Literature DB >> 31915121

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.

John G Hanly1, Murray B Urowitz2, Caroline Gordon3, Sang-Cheol Bae4, Juanita Romero-Diaz5, Jorge Sanchez-Guerrero2, Sasha Bernatsky6, Ann E Clarke7, Daniel J Wallace8, David A Isenberg9, Anisur Rahman9, Joan T Merrill10, Paul R Fortin11, Dafna D Gladman2, Ian N Bruce12, Michelle Petri13, Ellen M Ginzler14, Mary Anne Dooley15, Rosalind Ramsey-Goldman16, Susan Manzi17, Andreas Jönsen18, Graciela S Alarcón19, Ronald F van Vollenhoven20, Cynthia Aranow21, Meggan Mackay21, Guillermo Ruiz-Irastorza22, Sam Lim23, Murat Inanc24, Kenneth C Kalunian25, Søren Jacobsen26, Christine A Peschken27, Diane L Kamen28, Anca Askanase29, Vernon Farewell30.   

Abstract

OBJECTIVES: Using a reversible multistate model, we prospectively examined neuropsychiatric (NP) events for attribution, outcome and association with health-related quality of life (HRQoL), in an international, inception cohort of systemic lupus erythematosus (SLE) patients.
METHODS: Annual assessments for 19 NP events attributed to SLE and non-SLE causes, physician determination of outcome and patient HRQoL (short-form (SF)-36 scores) were measured. Time-to-event analysis and multistate modelling examined the onset, recurrence and transition between NP states.
RESULTS: NP events occurred in 955/1827 (52.3%) patients and 592/1910 (31.0%) unique events were attributed to SLE. In the first 2 years of follow-up the relative risk (95% CI) for SLE NP events was 6.16 (4.96, 7.66) and non-SLE events was 4.66 (4.01, 5.43) compared with thereafter. Patients without SLE NP events at initial assessment had a 74% probability of being event free at 10 years. For non-SLE NP events the estimate was 48%. The majority of NP events resolved over 10 years but mortality was higher in patients with NP events attributed to SLE (16%) versus patients with no NPSLE events (6%) while the rate was comparable in patients with non-SLE NP events (7%) compared with patients with no non-SLE events (6%). Patients with NP events had lower SF-36 summary scores compared with those without NP events and resolved NP states (p<0.001).
CONCLUSIONS: NP events occur most frequently around the diagnosis of SLE. Although the majority of events resolve they are associated with reduced HRQoL and excess mortality. Multistate modelling is well suited for the assessment of NP events in SLE. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autoimmune diseases; epidemiology; outcomes research; systemic lupus erythematosus

Mesh:

Year:  2020        PMID: 31915121     DOI: 10.1136/annrheumdis-2019-216150

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

Review 1.  Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management.

Authors:  Oshrat E Tayer-Shifman; Kathleen S Bingham; Zahi Touma
Journal:  Drugs Aging       Date:  2021-12-16       Impact factor: 3.923

2.  Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study.

Authors:  John Abel Engh; Thor Ueland; Ingrid Agartz; Dimitrios Andreou; Pål Aukrust; Birgitte Boye; Erlend Bøen; Ole Kristian Drange; Torbjørn Elvsåshagen; Sigrun Hope; Margrethe Collier Høegh; Inge Joa; Erik Johnsen; Rune Andreas Kroken; Trine Vik Lagerberg; Tove Lekva; Ulrik Fredrik Malt; Ingrid Melle; Gunnar Morken; Terje Nærland; Vidar Martin Steen; Kirsten Wedervang-Resell; Melissa Auten Weibell; Lars Tjelta Westlye; Srdjan Djurovic; Nils Eiel Steen; Ole Andreas Andreassen
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

3.  Role of autoantibodies and blood-brain barrier leakage in cognitive impairment in systemic lupus erythematosus.

Authors:  John G Hanly; Alexandra Legge; Lyna Kamintsky; Alon Friedman; Javeria A Hashmi; Steven D Beyea; John Fisk; Antonina Omisade; Cynthia Calkin; Tim Bardouille; Chris Bowen; Kara Matheson; Marvin J Fritzler
Journal:  Lupus Sci Med       Date:  2022-06

4.  The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?

Authors:  Marcello Govoni; John G Hanly
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

5.  Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.

Authors:  Laurent Arnaud; Maria G Tektonidou
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

6.  Case Report: Macrophage Activation Syndrome and Widespread Neuroimaging Abnormality in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Nana Shi; Xiangying Wang; Lixia Zou; Xinghui Yang; Qian Ma; Meiping Lu
Journal:  Front Pediatr       Date:  2021-12-14       Impact factor: 3.418

Review 7.  Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.

Authors:  Ronald van Vollenhoven; Anca D Askanase; Andrew S Bomback; Ian N Bruce; Angela Carroll; Maria Dall'Era; Mark Daniels; Roger A Levy; Andreas Schwarting; Holly A Quasny; Murray B Urowitz; Ming-Hui Zhao; Richard Furie
Journal:  Lupus Sci Med       Date:  2022-03

8.  Brain-Reactive Antibodies are Potential Biomarkers for Evaluating Therapeutic Efficacy in NPSLE Patients.

Authors:  Xiujiao Wang; Dongju Feng; Yao Ke; Lei Gu; Chengyin Lv; Miaojia Zhang; Qiang Wang; Yanyan Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-04       Impact factor: 2.989

9.  Concurrent Intracranial Hypertension and Bilateral Optic Neuritis in a Patient With Systemic Lupus Erythematosus: A Case Report.

Authors:  Worapot Srimanan; Somboon Panyakorn
Journal:  Clin Med Insights Case Rep       Date:  2022-09-06

10.  Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort.

Authors:  John G Hanly; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Andreas Jonsen; Graciela S Alarcón; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2021-10-29       Impact factor: 15.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.